Opus Genetics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Opus Genetics kazanç ve gelirinin sırasıyla yıllık 30.9% ve 48.1% oranında artması tahmin edilirken, EPS'nin yıllık 35.1% oranında büyümesi bekleniyor.

Anahtar bilgiler

30.9%

Kazanç büyüme oranı

35.10%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.6%
Gelir büyüme oranı	48.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	08 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Feb 07

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders have had their patience rewarded with a 43% share price jump in the...

Analiz Makalesi • Dec 11

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 27% in...

Analiz Makalesi • Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 31% in...

Analiz Makalesi • Jul 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc.'s ( NASDAQ:IRD ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right now...

Analiz Makalesi • May 19

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

Investors in Opus Genetics, Inc. ( NASDAQ:IRD ) had a good week, as its shares rose 7.4% to close at US$1.02 following...

Analiz Makalesi • Apr 09

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Opus Genetics, Inc. ( NASDAQ:IRD ) share price has dived 25% in the last...

Analiz Makalesi • Aug 19

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...

Analiz Makalesi • Jul 24

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders have had their patience rewarded with a 30% share price jump in the...

Analiz Makalesi • Jul 12

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • May 02

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) share price has dived 26% in the last...

Analiz Makalesi • Mar 15

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders that were waiting for something to happen have been dealt a blow...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:IRD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	28	-67	-24	-27	10
12/31/2027	16	-56	-43	-44	13
12/31/2026	15	-49	-42	-61	15
12/31/2025	14	-50	-35	-35	N/A
9/30/2025	15	-68	-33	-33	N/A
6/30/2025	15	-58	-32	-32	N/A
3/31/2025	14	-59	-29	-29	N/A
12/31/2024	11	-58	-26	-26	N/A
9/30/2024	8	-27	-14	-14	N/A
6/30/2024	16	-14	-11	-11	N/A
3/31/2024	19	-11	-3	-3	N/A
12/31/2023	19	-10	-1	-1	N/A
9/30/2023	57	29	23	23	N/A
6/30/2023	45	19	22	22	N/A
3/31/2023	42	19	17	17	N/A
12/31/2022	40	18	14	14	N/A
9/30/2022	N/A	-22	-20	-20	N/A
6/30/2022	0	-22	-19	-19	N/A
3/31/2022	1	-24	-20	-20	N/A
12/31/2021	1	-57	-19	-19	N/A
9/30/2021	1	-69	-20	-18	N/A
6/30/2021	0	-66	-17	-16	N/A
3/31/2021	N/A	-61	-13	-12	N/A
12/31/2020	N/A	-25	-8	-7	N/A
9/30/2020	N/A	-8	-4	-4	N/A
6/30/2020	N/A	-9	-4	-4	N/A
3/31/2020	N/A	-8	-4	-4	N/A
12/31/2019	N/A	-6	-4	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IRD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: IRD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: IRD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: IRD şirketinin gelirinin (yıllık 48.1% ) US pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IRD şirketinin gelirinin (yıllık 48.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IRD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/11 12:30
Gün Sonu Hisse Fiyatı	2026/05/08 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Opus Genetics, Inc. 14 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 19%, revenue upgraded

Price target increased by 7.5% to US$9.50

Price target increased by 14% to US$8.83

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to US$6.80

Consensus revenue estimates decrease by 18%, EPS upgraded

Recent updates

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

High number of new directors

Consensus EPS estimates fall by 19%, revenue upgraded

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Price target increased by 7.5% to US$9.50

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 14% to US$8.83

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

New minor risk - Share price stability

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Independent Chairman recently bought US$324k worth of stock

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology